Form 4 for VRTX Vertex Pharmaceuticals
Accepted 2022-04-06 00:00:00 ET · period of report 2022-04-04 · accession 0000899243-22-014120 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| M | 2022-04-06 | 2022-04-04+ | VRTX | Sanna Bastiano | EVP, Cell, Genetic Therapies | S - Sale | $274.10 | -3,725 | 46.8K | -7% | -$1.02M |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2022-04-05 | S | D | 3,163 | $275.23 | 43,343 | D | — | — | (F5) Open market sales reported on this line occurred at a weighted average price of $275.23 (range $275.00 to $275.66). (F2) Mr. Sanna undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. |
| 2 | Common | Common Stock | 2022-04-04 | S | D | 257 | $268.43 | 46,506 | D | — | — | (F4) Open market sales reported on this line occurred at a weighted average price of $268.43 (range $267.81 to $268.78). (F2) Mr. Sanna undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. |
| 3 | Common | Common Stock | 2022-04-04 | S | D | 305 | $267.10 | 46,763 | D | — | — | (F3) Open market sales reported on this line occurred at a weighted average price of $267.10 (range $266.66 to $267.57). (F2) Mr. Sanna undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. |